Valneva SE is a specialty vaccine company focused on developing and commercializing innovative vaccines for infectious diseases
The company is committed to addressing significant unmet medical needs through its diverse pipeline of vaccine candidates, which includes programs for diseases such as Lyme disease and chikungunya. Valneva employs advanced technologies and extensive research to create safe and effective vaccines that aim to improve public health outcomes globally. By collaborating with various health organizations and leveraging its expertise in vaccine development, Valneva seeks to contribute to the prevention of infectious diseases and foster better health through vaccination.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.
Pfizer Inc. (NYSEPFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSEPFE) today announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSEPFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with inclusion of pediatric participants in their planned Phase 3 trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in the third quarter of 2022, subject to regulatory approval.
San Diego, CA -- (SBWIRE) -- 11/08/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Valneva SE.
San Diego, CA -- (SBWIRE) -- 09/27/2021 -- Valneva SE is under investigation over possible securities laws violations by in connection with certain financial statements.
